Olumiant Receives Positive Opinion for Treating Severe Alopecia Areata in Adolescents
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy LLY?
Source: Newsfilter
- Clinical Trial Results: The Phase 3 BRAVE-AA-PEDS study demonstrated that 42% of patients with severe alopecia areata achieved 80% or more scalp hair coverage at 36 weeks, indicating Olumiant's effectiveness in this vulnerable adolescent population and potentially providing a new treatment option.
- Regulatory Progress: The European Medicines Agency (EMA) has issued a positive opinion for Olumiant's use in adolescents aged 12 to under 18 with severe alopecia areata, with a final decision expected in the next one to two months, which will further facilitate market access for Olumiant.
- Significant Treatment Effects: Olumiant enabled many adolescents to achieve near-complete scalp hair regrowth within 36 weeks, with 50% of patients successfully regrowing eyebrows and 42.9% regrowing eyelashes, showcasing its potential to improve patients' quality of life.
- Broad Market Prospects: Lilly has submitted an application to the U.S. FDA for Olumiant to treat severe alopecia areata in adolescents, with a decision anticipated in the second half of 2026, which, if approved, will provide an important evidence-based treatment option for young patients.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1051.990
Low
950.00
Averages
1192
High
1500
Current: 1051.990
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, markets, and sells pharmaceutical products worldwide. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company is also engaged in radiopharmaceutical discovery, development, and manufacturing efforts, and clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). It is evaluating its novel gene therapy candidate, ixoberogene soroparvovec.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly Approaches $1 Trillion Valuation
- Price Target Analysis: Analysts currently project Eli Lilly's price target to be just under $1,230, indicating approximately 17% upside from its current price of $1,031.79, which presents a potential return opportunity for investors.
- Growth Drivers: The strong growth of Eli Lilly's GLP-1 drugs, Zepbound and Mounjaro, has fueled bullish sentiment, as investors grow confident in the company's potential to dominate the anti-obesity drug market, thereby continuing to drive the stock's rally.
- Valuation Considerations: Despite Eli Lilly's market cap nearing $1 trillion, its price-to-earnings ratio stands at 46, significantly higher than the S&P 500 average of 25, suggesting that much of the future growth is already priced in, which could lead to correction risks if expectations are not met.
- Long-term Investment Advice: For long-term investors, Eli Lilly remains a solid investment option, but it is crucial to temper expectations to avoid overestimating future gains, especially given the current high valuation context.
See More
Analysis of Growth Drivers in the Biliary Tract Cancer Market
- Market Size Growth: The biliary tract cancer market is projected to reach $1.1 billion in 2024, with the U.S. accounting for approximately 60% of this market, indicating a strong demand for new therapies in this leading region.
- Emerging Drug Launches: The introduction of new drugs such as Tinengotinib and Rilvegostomig is expected to further drive market growth, particularly in the areas of targeted therapies and immuno-oncology, enhancing treatment options for patients.
- Advancements in Diagnostic Technology: Improvements in imaging techniques like MRI, endoscopic ultrasound, and PET have enhanced the accuracy of biliary tract cancer diagnoses, enabling earlier detection and personalized treatment approaches, thereby improving patient outcomes.
- Market Dynamics in Treatment: By 2034, chemotherapy is expected to remain the primary revenue source for biliary tract cancer treatment, and the introduction of new therapies will alter the competitive landscape, fostering medical innovation and economic growth.
See More
Teva Pharmaceutical Stock Doubles, Strong Outlook Ahead
- Earnings Beat: Teva Pharmaceutical reported fourth-quarter revenue of $4.7 billion for 2025, an 11% year-over-year increase, with adjusted EPS at $0.96, significantly surpassing the analyst forecast of $0.64, indicating robust financial performance and market demand.
- Strategic Shift: Teva is pivoting from generic drugs to specialty pharmaceuticals, with strong sales from branded drugs like Austedo, Ajovy, and Uzedy offsetting flat generic sales, and these products are expected to comprise a larger share of revenue, enhancing overall profitability.
- Future Growth Potential: Management anticipates that the drug candidate duvakitug could achieve peak annual sales of $2 billion to $5 billion, and with other pipeline candidates, the total sales potential exceeds $10 billion, showcasing Teva's strong competitive position in the future market.
- Attractive Valuation: Currently trading at around 12.5 times forward earnings, Teva is positioned in the middle to lower end of the pharmaceutical valuation range, providing long-term investors an opportunity to enter before potential price appreciation, especially if the stock price dips.
See More
CrowdStrike and Eli Lilly Options Trading Active
- CrowdStrike Options Volume: As of now, CrowdStrike Holdings Inc (CRWD) options have reached a trading volume of 25,887 contracts, equivalent to approximately 2.6 million shares, representing a significant 53.7% of its average daily trading volume over the past month, indicating strong market interest in the stock.
- High Strike Options Activity: Within CRWD, the $400 strike call option has been particularly active, with 1,316 contracts traded today, representing about 131,600 underlying shares, reflecting investor expectations for future price increases.
- Eli Lilly Options Volume: Concurrently, Eli Lilly (LLY) options have shown a trading volume of 19,886 contracts, approximately 2.0 million shares, accounting for 52.5% of its average daily trading volume over the past month, highlighting the stock's market activity.
- High Strike Options Focus: For LLY, the $1100 strike call option has also been notably active, with 1,461 contracts traded today, representing around 146,100 shares, indicating optimistic sentiment among investors regarding the stock's future performance.
See More
Eli Lilly Achieves $1 Trillion Valuation, Remarkable Returns Over a Decade
- Innovation-Driven Growth: Eli Lilly has achieved remarkable returns over the past decade, becoming the largest healthcare stock globally and the first to surpass a $1 trillion valuation, showcasing its leadership in the industry through significant breakthroughs in diabetes and weight management.
- Diversification Strategy: While diabetes drugs are currently the main growth driver, Lilly is actively expanding into oncology, aiming to mitigate future patent cliffs through a diversified product portfolio, thereby ensuring long-term business stability and growth potential.
- Technological Investment Outlook: Lilly's partnership with Nvidia aims to create the pharmaceutical industry's most powerful AI supercomputer and establish a research lab, focusing on accelerating the discovery and development of breakthrough therapies, which, although may not yield immediate returns, lays a solid foundation for the future.
- Attractive Dividend Policy: Having more than doubled its dividends in the past five years, Lilly demonstrates strong financial health, and long-term investors can significantly boost total returns through dividend reinvestment, further solidifying its core position in a diversified investment portfolio.
See More
Eli Lilly's Innovations and Dividend Growth Outlook
- Innovation-Driven Growth: Eli Lilly has achieved significant breakthroughs in diabetes and weight management, propelling it to become the largest healthcare stock globally and the first to reach a $1 trillion valuation, showcasing its strong market position and future growth potential.
- Diversification Strategy: While currently relying on the success of tirzepatide, Lilly is actively expanding into oncology, aiming to mitigate future patent cliffs through a diversified product lineup, thereby enhancing its long-term competitiveness.
- Technology Investment: Lilly is partnering with Nvidia to build the pharmaceutical industry's most powerful AI supercomputer and research lab, aimed at accelerating the discovery and development of breakthrough therapies; these investments may not yield immediate results but lay a solid foundation for the future.
- Dividend Growth: Over the past five years, Lilly has more than doubled its dividends, reflecting its strong financial health, and long-term investors can significantly boost total returns through dividend reinvestment, further solidifying its position as a core holding in investment portfolios.
See More
Eli Lilly Approaches $1 Trillion Valuation
- Price Target Analysis: Analysts currently project Eli Lilly's price target to be just under $1,230, indicating approximately 17% upside from its current price of $1,031.79, which presents a potential return opportunity for investors.
- Growth Drivers: The strong growth of Eli Lilly's GLP-1 drugs, Zepbound and Mounjaro, has fueled bullish sentiment, as investors grow confident in the company's potential to dominate the anti-obesity drug market, thereby continuing to drive the stock's rally.
- Valuation Considerations: Despite Eli Lilly's market cap nearing $1 trillion, its price-to-earnings ratio stands at 46, significantly higher than the S&P 500 average of 25, suggesting that much of the future growth is already priced in, which could lead to correction risks if expectations are not met.
- Long-term Investment Advice: For long-term investors, Eli Lilly remains a solid investment option, but it is crucial to temper expectations to avoid overestimating future gains, especially given the current high valuation context.
See More
Analysis of Growth Drivers in the Biliary Tract Cancer Market
- Market Size Growth: The biliary tract cancer market is projected to reach $1.1 billion in 2024, with the U.S. accounting for approximately 60% of this market, indicating a strong demand for new therapies in this leading region.
- Emerging Drug Launches: The introduction of new drugs such as Tinengotinib and Rilvegostomig is expected to further drive market growth, particularly in the areas of targeted therapies and immuno-oncology, enhancing treatment options for patients.
- Advancements in Diagnostic Technology: Improvements in imaging techniques like MRI, endoscopic ultrasound, and PET have enhanced the accuracy of biliary tract cancer diagnoses, enabling earlier detection and personalized treatment approaches, thereby improving patient outcomes.
- Market Dynamics in Treatment: By 2034, chemotherapy is expected to remain the primary revenue source for biliary tract cancer treatment, and the introduction of new therapies will alter the competitive landscape, fostering medical innovation and economic growth.
See More
Teva Pharmaceutical Stock Doubles, Strong Outlook Ahead
- Earnings Beat: Teva Pharmaceutical reported fourth-quarter revenue of $4.7 billion for 2025, an 11% year-over-year increase, with adjusted EPS at $0.96, significantly surpassing the analyst forecast of $0.64, indicating robust financial performance and market demand.
- Strategic Shift: Teva is pivoting from generic drugs to specialty pharmaceuticals, with strong sales from branded drugs like Austedo, Ajovy, and Uzedy offsetting flat generic sales, and these products are expected to comprise a larger share of revenue, enhancing overall profitability.
- Future Growth Potential: Management anticipates that the drug candidate duvakitug could achieve peak annual sales of $2 billion to $5 billion, and with other pipeline candidates, the total sales potential exceeds $10 billion, showcasing Teva's strong competitive position in the future market.
- Attractive Valuation: Currently trading at around 12.5 times forward earnings, Teva is positioned in the middle to lower end of the pharmaceutical valuation range, providing long-term investors an opportunity to enter before potential price appreciation, especially if the stock price dips.
See More
CrowdStrike and Eli Lilly Options Trading Active
- CrowdStrike Options Volume: As of now, CrowdStrike Holdings Inc (CRWD) options have reached a trading volume of 25,887 contracts, equivalent to approximately 2.6 million shares, representing a significant 53.7% of its average daily trading volume over the past month, indicating strong market interest in the stock.
- High Strike Options Activity: Within CRWD, the $400 strike call option has been particularly active, with 1,316 contracts traded today, representing about 131,600 underlying shares, reflecting investor expectations for future price increases.
- Eli Lilly Options Volume: Concurrently, Eli Lilly (LLY) options have shown a trading volume of 19,886 contracts, approximately 2.0 million shares, accounting for 52.5% of its average daily trading volume over the past month, highlighting the stock's market activity.
- High Strike Options Focus: For LLY, the $1100 strike call option has also been notably active, with 1,461 contracts traded today, representing around 146,100 shares, indicating optimistic sentiment among investors regarding the stock's future performance.
See More
Eli Lilly Achieves $1 Trillion Valuation, Remarkable Returns Over a Decade
- Innovation-Driven Growth: Eli Lilly has achieved remarkable returns over the past decade, becoming the largest healthcare stock globally and the first to surpass a $1 trillion valuation, showcasing its leadership in the industry through significant breakthroughs in diabetes and weight management.
- Diversification Strategy: While diabetes drugs are currently the main growth driver, Lilly is actively expanding into oncology, aiming to mitigate future patent cliffs through a diversified product portfolio, thereby ensuring long-term business stability and growth potential.
- Technological Investment Outlook: Lilly's partnership with Nvidia aims to create the pharmaceutical industry's most powerful AI supercomputer and establish a research lab, focusing on accelerating the discovery and development of breakthrough therapies, which, although may not yield immediate returns, lays a solid foundation for the future.
- Attractive Dividend Policy: Having more than doubled its dividends in the past five years, Lilly demonstrates strong financial health, and long-term investors can significantly boost total returns through dividend reinvestment, further solidifying its core position in a diversified investment portfolio.
See More
Eli Lilly's Innovations and Dividend Growth Outlook
- Innovation-Driven Growth: Eli Lilly has achieved significant breakthroughs in diabetes and weight management, propelling it to become the largest healthcare stock globally and the first to reach a $1 trillion valuation, showcasing its strong market position and future growth potential.
- Diversification Strategy: While currently relying on the success of tirzepatide, Lilly is actively expanding into oncology, aiming to mitigate future patent cliffs through a diversified product lineup, thereby enhancing its long-term competitiveness.
- Technology Investment: Lilly is partnering with Nvidia to build the pharmaceutical industry's most powerful AI supercomputer and research lab, aimed at accelerating the discovery and development of breakthrough therapies; these investments may not yield immediate results but lay a solid foundation for the future.
- Dividend Growth: Over the past five years, Lilly has more than doubled its dividends, reflecting its strong financial health, and long-term investors can significantly boost total returns through dividend reinvestment, further solidifying its position as a core holding in investment portfolios.
See More
